Business
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n \n \n \n InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol \"INM\"\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n VANCOUVER, BC, Nov. 12, 2020\n \n \n \n \n \n VANCOUVER, BC\n \n ,\n \n Nov. 12, 2020\n \n /CNW/ -\n \n InMed Pharmaceuticals Inc.\n \n (\"InMed\" or the \"Company\") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (\"CBN\"), today announced that it has priced a public offering of an aggregate of 1,780,000 common shares, together with accompanying warrants to purchase up to an aggregate of 1,780,000 common shares, at a public offering price of\n \n US$4.50\n \n per share and accompanying warrant. Each common share will be sold in the offering with one warrant to purchase one common share. The warrants have an exercise price of\n \n US$5.11\n \n per share, are immediately exercisable upon issuance, and expire six years following the date of issuance. The underwriters have also been granted an option to purchase an additional 267,000 common shares and additional warrants to purchase up to an aggregate of 267,000 common shares for a period of 45 days.\n \n \n \n \n \n \n \n \n \n InMed's common shares commence trading on the Nasdaq Capital Market (Nasdaq) effective today under the symbol \"INM\".\n \n \n The offering is expected to close on\n \n November 16, 2020\n \n , subject to customary closing conditions.\n \n \n Roth Capital Partners is acting as sole book-running manager for the offering and Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as co-manager.\n \n \n InMed anticipates its gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, to be approximately\n \n US$8 million\n \n , excluding any exercise of the underwriters' option to purchase additional securities.\n \n \n InMed intends to use the net proceeds from the offering,...